Downloads

  1. Reveleris® Prep Purification System
    7/18/2014

    A high-performance system with integrated flash and preparative LC in a single compact system

  2. Securing Provision K Status For A Client’s API Helps To Expedite Shipping And Reduce US Importation Costs
    7/17/2014

    Active pharmaceutical ingredients (APIs) also known as bulk active pharmaceutical ingredients, are defined by the US Food and Drugs Administration (FDA) as ‘any component that provides pharmacological activity or other effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body of man or animals.’ Generally, APIs are therapeutic components of drug formulations or finished pharmaceutical products that also contain fillers, binders’ excipients and other inactive ingredients. APIs are routinely evaluated or used by pharmaceutical companies for preclinical testing during new drug development, human clinical trials testing and commercial manufacturing of approved pharmaceutical products.

  3. Emphaze™ AEX Hybrid Purifier
    7/9/2014

    The Emphaze Hybrid Purifier is a new single-use clarifying device containing a multi-mechanism all synthetic Q-functional anion exchange media integrated with a fine particle, bioburden reduction membrane. The anion exchange media is comprised of a quaternary amine hydrogel supported by a fine fiber nonwoven scaffold. A combination of 3M technology platforms enables the hyperfunctionalization of a high purity polypropylene nonwoven with a covalently attached, thermally stable, water soluble polymer; the functional polymer accounts for roughly two-thirds of the mass of the anion exchange media. The bioburden reduction membrane is a highly asymmetric, high loading capacity polyamide membrane which has nine zones of decreasing pore size spanning a roughly 20X range and terminating with a 0.2 μm bioburden reduction rated pore size.

  4. Emphaze™ AEX Hybrid Purifier Datasheet
    7/9/2014

    The Emphaze Hybrid Purifier is a new single-use clarifying device containing a multi-mechanism all synthetic Q-functional anion exchange media integrated with a fine particle, bioburden reduction membrane. The anion exchange media is comprised of a quaternary amine hydrogel supported by a fine fiber nonwoven scaffold. A combination of 3M technology platforms enables the hyperfunctionalization of a high purity polypropylene nonwoven with a covalently attached, thermally stable, water soluble polymer; the functional polymer accounts for roughly two-thirds of the mass of the anion exchange media. The bioburden reduction membrane is a highly asymmetric, high loading capacity polyamide membrane which has nine zones of decreasing pore size spanning a roughly 20X range and terminating with a 0.2 μm bioburden reduction rated pore size.

  5. Utilization Of Customs Warehouses In The Clinical Trial Supply Chain
    7/3/2014

    The global clinical trial supply chain industry has been seeking new opportunities to improve efficiency for many years. As pressures to decrease cost and reduce time to market continue to rise, the design of the clinical trial supply chain must evolve and change to meet those demands.

  6. Epoch™ 2 Microplate Spectrophotometer
    7/3/2014

    Epoch™ 2 is a compact microplate spectrophotometer that combines modern touchscreen technology with excellent performance for UV-Vis measurements in 6- to 384-well microplates, cuvettes and in micro-volume samples with the available Take3™ plate. No need to worry about limited onboard software, since Epoch 2 comes with full function Gen5™ software, ready to read and analyze data at the touch of a few buttons! For maximum versatility, Epoch 2 can read from 200 nm to 999 nm in 1 nm increments for single, dual and multi-wavelength measurements in end point and kinetic read methods.

  7. Epoch™ 2 Microplate Spectrophotometer Datasheet
    7/3/2014

    Epoch™ 2 is a compact microplate spectrophotometer that combines modern touchscreen technology with excellent performance for UV-Vis measurements in 6- to 384-well microplates, cuvettes and in micro-volume samples with the available Take3™ plate.

  8. 5 Most Logistically Challenging Biopharm Commodities
    6/16/2014

    For several years, the pharmaceutical industry has been moving away from primarily chemical and synthesized based drugs toward biologics. And while research and development is complex for all types of drug therapies, biologics have special challenges since they are made of up living microorganisms and cells. This is especially true where logistics is concerned – whether related to R&D, clinical trials or, ultimately, getting a drug to market.

  9. Industry Perceptions Of Integrated Continuous Biopharma Manufacturing
    6/12/2014
  10. EMC® Documentum® Research And Development
    6/11/2014

    Streamlining the regulatory submission process is essential to getting products to market faster today. But you need to create, review and maintain essential submission-related documentation appropriately, even as regulatory rules and requirements vary and evolve by country and region. And if you’ve outsourced to contract research organizations (CROs), your submission process must enable reliable, seamless collaboration with these resources.

Newsletter Signup
Newsletter Signup